Effects of Sodium Arsenite on the Myocardial Differentiation in Mouse Embryonic Bodies

Jeong, Sunhwa; Ahn, Changhwan; Kwon, Jin-Sook; Kim, KangMin; Jeung, Eui‐Bae

doi:10.3390/toxics11020142

Cited by 4 publications

(1 citation statement)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many rodent studies have not been able to replicate some of the findings associated with in-utero exposure of iAs on development in humans, indicating that there are differences between the two species, and this should be taken into consideration when interpreting these findings. iAs has also been shown to target mitochondria and affect cellular metabolism [89][90][91][92][93][94] . Shifts in metabolism in the heart during pregnancy have been shown to be essential for cardiac hypertrophy 45,[95][96][97][98][99] .…”

Section: Limitationsmentioning

confidence: 99%

Prenatal Arsenite Exposure Alters Maternal Cardiac Remodeling During Late Pregnancy

Taube,

Kabir,

Ebenebe

et al. 2023

Preprint

View full text Add to dashboard Cite

Exposure to inorganic arsenic through drinking water is widespread and has been linked to many chronic diseases, including cardiovascular disease. Arsenic exposure has been shown to alter hypertrophic signaling in the adult heart, as well as in-utero offspring development. However, the effect of arsenic on maternal cardiac remodeling during pregnancy has not been studied. As such, there is a need to understand how environmental exposure contributes to adverse pregnancy-related cardiovascular events. This study seeks to understand the impact of trivalent inorganic arsenic exposure during gestation on maternal cardiac remodeling in late pregnancy, as well as offspring outcomes. C57BL/6J mice were exposed to 0 (control), 100 or 1000 µg/L sodium arsenite (NaAsO2) beginning at embryonic day (E) 2.5 and continuing through E17.5. Maternal heart function and size were assessed via transthoracic echocardiography, gravimetric measurement, and histology. Transcript levels of hypertrophic markers were probed via qRT-PCR and confirmed by western blot. Offspring outcomes were assessed through echocardiography and gravimetric measurement. We found that exposure to 1000 µg/L iAs abrogated normal physiologic growth of the maternal heart during late pregnancy and reduced transcript levels of estrogen receptor alpha (ERα), progesterone receptor membrane component 1 (Pgrmc1) and progesterone receptor membrane component 2 (Pgrmc2). Both 100 and 1000 µg/L iAs also reduced transcription of protein kinase B (Akt) and atrial natriuretic peptide (ANP). Akt protein expression was also significantly reduced after 1000 µg/L iAs exposure in the maternal heart with no change in activating phosphorylation. This significant abrogation of maternal cardiac hypertrophy suggests that arsenic exposure during pregnancy can potentially contribute to cardiovascular disease. Taken together, our findings further underscore the importance of reducing arsenic exposure during pregnancy and indicate that more research is needed to assess the impact of arsenic and other environmental exposures on the maternal heart and adverse pregnancy events.

show abstract